Johnson & Johnson Stock Price, News & Analysis

Dean Omar Branham Shirley trial attorney Aaron Chapman has been recognized in the 2025 Lawdragon 500 X – The Next Generation legal guide for his work in plaintiff litigation. Chapman was part of a trial team that secured an $8 million verdict against Johnson & Johnson (NYSE: JNJ) in Suffolk County, Mass., representing a woman who developed mesothelioma from talcum powder products.

The attorney has notable experience in asbestos litigation across multiple states and previously helped secure the largest asbestos-related personal injury verdict in Nevada in 2021. The recognition by Lawdragon highlights emerging legal leaders selected through nominations, research, and peer recommendations.

Johnson & Johnson (NYSE: JNJ) has announced its quarterly dividend for Q3 2025. The company's Board of Directors has declared a cash dividend of $1.30 per share on its common stock. The dividend will be paid on September 9, 2025 to shareholders of record as of August 26, 2025, which is also the ex-dividend date.

Johnson & Johnson (NYSE: JNJ) reported strong Q2 2025 results with reported sales growth of 5.8% to $23.7 billion and adjusted EPS of $2.77. The company raised its 2025 guidance, increasing estimated reported sales by $2 billion to 5.4% growth and adjusted EPS to $10.85 at midpoint.

Performance was driven by growth in both segments: Innovative Medicine sales grew 3.8% operationally, led by DARZALEX, CARVYKTI, and TREMFYA, while MedTech sales increased 6.1% operationally, with strong performance in cardiovascular and general surgery products.

Notable achievements include FDA approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, and positive CARVYKTI data in multiple myeloma. The company anticipates significant pipeline progress in H2 2025 across multiple therapeutic areas.

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental New Drug Application (sNDA) to the FDA for CAPLYTA® (lumateperone) based on impressive Phase 3 trial results in schizophrenia relapse prevention. The study demonstrated a 63% reduction in relapse risk compared to placebo, with significantly longer time to relapse during the 26-week double-blind treatment phase (p=0.0002).

The trial's safety profile remained consistent with existing clinical data, with headache being the most common adverse event. CAPLYTA® is already FDA-approved for schizophrenia treatment and is the first approved therapy for both bipolar I and II depression. The drug's mechanism involves high serotonin 5-HT2A receptor occupancy and lower dopamine D2 receptor occupancy at therapeutic doses.

Johnson & Johnson (JNJ) announced new data showing IMAAVY (nipocalimab-aahu) demonstrated superior sustained disease control compared to other FcRn blockers in treating generalized myasthenia gravis (gMG). The indirect treatment comparison (ITC) revealed IMAAVY achieved comparable symptom relief at Week 1 and showed greater or statistically significant improvement in MG-ADL scores versus competitors over 24 weeks. IMAAVY, which received FDA approval for treating both adult and pediatric gMG patients aged 12 and older, features a predictable biweekly dosing regimen. The drug showed significantly greater mean improvements versus one comparator at Weeks 8-24 and another at Weeks 10-14, with population-adjusted ITCs showing favorable results for IMAAVY. This data strengthens IMAAVY's position as a treatment option for gMG patients, particularly given its broad approval for both anti-AChR and anti-MuSK antibody positive patients.

A Suffolk County jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $8 million in damages to Janice Paluzzi, an 84-year-old Massachusetts woman who developed mesothelioma after long-term use of J&J's talcum powder products. The jury found J&J liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talc products caused Paluzzi's terminal cancer. Evidence presented during the trial revealed that J&J had internal knowledge of asbestos contamination in its talc supply for decades but continued marketing the products as safe. The company discontinued talc-based products in the US in 2020. Paluzzi, who used J&J's Baby Powder on herself and her seven children, was diagnosed with mesothelioma in 2021.

Johnson & Johnson announced promising results from Phase 2 RedirecTT-1 study evaluating the combination of TALVEY and TECVAYLI in multiple myeloma patients with extramedullary disease (EMD). The study showed a high overall response rate (ORR) of 78.9% in heavily pretreated patients, with 54.4% achieving complete response or better. The trial, involving 90 patients, demonstrated durable responses with 61% of patients progression-free at one year and 74.5% survival rate. The combination therapy showed efficacy even in patients previously treated with BCMA CAR-T therapy (83.3% ORR) or anti-FcRH5 bispecific antibodies (75% ORR). The safety profile aligned with previous monotherapy results, with manageable side effects and low discontinuation rates.

Johnson & Johnson announced promising first clinical data from a Phase 1b study of JNJ-90014496, a novel dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. The therapy showed impressive efficacy with 80% complete response rate in patients with one prior treatment line and 75% in those with two or more prior treatments. At the recommended Phase 2 dose of 75 million CAR+ T-cells, the therapy demonstrated a favorable safety profile with no Grade 3/4 cytokine release syndrome observed. The study involved 22 patients for efficacy assessment, achieving 100% objective response rate in single prior therapy patients and 92% in multiple prior therapy patients. This development represents a potential advancement over current single-antigen CAR T therapies, which typically achieve only 40% long-term remission rates.

Johnson & Johnson announced promising Phase 1b data for bleximenib (JNJ-75276617), an investigational selective menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid leukemia (AML). The study evaluated 125 patients with KMT2A gene rearrangements or NPM1 gene mutations. At the recommended Phase 2 dose of 100mg twice daily, relapsed/refractory AML patients showed an 82% overall response rate and 59% complete response rate, while newly diagnosed patients achieved 90% and 75% respectively. The safety profile was favorable, with only 4% of patients experiencing differentiation syndrome and no significant QTc prolongation. Common adverse events included nausea (65%), thrombocytopenia (61%), neutropenia (59%), and anemia (49%).